There was no credible evidence that Gates has been granted approval, secret or otherwise, to spray RNA (including mRNA, a ...

Regulators block Duchenne muscular dystrophy treatment after fatal side-effects outweigh questionable efficacy ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.

STUTTGART, Germany I July 30, 2025 I La Merie Publishing released its newest product entitled: Glypican-3 (GPC3) Targeted Therapy: a Competitor Analysis.